Home › Funds › Privium Fund Management B.V. › RCKT

Privium Fund Management B.V. position in RCKT

ROCKET PHARMACEUTICALS INC · Health Care

Privium Fund Management B.V. reported holding 244,146 shares of RCKT (ROCKET PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$642K, representing 0.12% of its reported portfolio and ranking #45 among its reported holdings. Privium Fund Management B.V. has disclosed RCKT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)244.15K sh
Reported value held$642.10K
Portfolio Weight0.12%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Privium Fund Management B.V.'s RCKT position evolved

Privium Fund Management B.V. first disclosed a stake in RCKT in Q3 2023 at 143,350 shares (US$2.9M). The position peaked in Q4 2023 at 233,050 shares, worth US$6.9M. Across 13 filings, Privium Fund Management B.V. increased the stake 8 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 244,146 shares valued at US$642K. Notable position changes include a 63% increase in Q4 2023 (shares fell 10% over the following quarter), a 61% trim in Q4 2025 (shares rose 2% over the following quarter), a 42% increase in Q1 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 143.35K $2.94M New
Q4 2023 233.05K $6.87M Add
Q1 2024 235.05K $6.33M Add
Q2 2024 250.98K $4.96M Add
Q3 2024 294.80K $5.44M Add
Q4 2024 397.65K $5.00M Add
Q1 2025 432.76K $2.89M Add
Q2 2025 432.76K $1.12M Hold
Q3 2025 432.76K $1.41M Hold
Q4 2025 170.15K $597.21K Reduce
Q1 2026 242.15K $866.88K Add
Q2 2026 244.15K $834.98K Add
Q3 2026 244.15K $642.10K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RCKT and 13F data

RCKT (ROCKET PHARMACEUTICALS INC) is a Health Care company. 15 other funds we track also report a position in RCKT — the largest reported positions include RTW INVESTMENTS, LP (US$60.5M), Newtyn Management, LLC (US$13.7M), Maverick Capital (US$13.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RCKT

All RCKT fund holders →

FAQ

How long has Privium Fund Management B.V. held RCKT?

Privium Fund Management B.V. has disclosed RCKT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Privium Fund Management B.V.'s current position in RCKT?

As of Q3 2026, Privium Fund Management B.V. holds 244.15K shares of RCKT (ROCKET PHARMACEUTICALS INC), valued at $642.10K, representing 0.12% of its reported portfolio and ranking #45.

Has Privium Fund Management B.V. been buying or selling RCKT?

In the latest 13F filing (Q3 2026), Privium Fund Management B.V. held unchanged its position in RCKT. The position peaked in Q4 2023 at 233.05K shares.

Which other funds hold RCKT?

Other major institutional holders of RCKT include RTW INVESTMENTS, LP, Newtyn Management, LLC, Maverick Capital, among 15 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.